亚洲与非亚洲地区直接口服抗凝药与华法林疗效和安全性比较:系统综述与Meta回归分析
该系统综述与Meta回归分析纳入11项随机对照试验、共60,400例非瓣膜性房颤患者,比较DOACs与华法林的疗效和安全性。结果显示亚洲地区DOACs在降低卒中/体循环栓塞和大出血方面优于华法林,且地区差异在疗效上显著、在安全性上经Meta回归调整后不显著。
要点
- 亚洲地区DOACs较华法林显著降低卒中/体循环栓塞风险(RR 0.62,95%CI 0.49-0.78)。
- 亚洲地区DOACs较华法林显著降低大出血风险(RR 0.62,95%CI 0.51-0.75)。
- Meta回归调整个体背景后,地区差异仅见于疗效,未见药物安全性差异。
核心结论
- DOACs在亚洲地区治疗非瓣膜性房颤可能比华法林更有效。
- 亚洲与非亚洲地区的疗效差异显著,但安全性差异经Meta回归调整后不显著。
研究设计与样本
- 系统综述、Meta分析与Meta回归分析,检索2019年8月前发表的随机对照试验。
- 共纳入11项研究,包括7,118例亚洲患者和53,282例非亚洲患者,总计60,400例非瓣膜性房颤患者。
主要发现
- 亚洲地区DOACs对比华法林降低卒中/体循环栓塞的RR为0.62(95%CI 0.49-0.78),非亚洲地区RR为0.83(95%CI 0.75-0.92),交互P=0.02。
- 亚洲地区DOACs对比华法林降低大出血的RR为0.62(95%CI 0.51-0.75),非亚洲地区RR为0.90(95%CI 0.76-1.05),交互P=0.004。
- Meta回归分析调整各研究个体背景后,地区差异在疗效方面存在,在药物安全性方面未观察到。
临床怎么用
- 对于亚洲非瓣膜性房颤患者,可优先考虑DOACs而非华法林以降低卒中/体循环栓塞和大出血风险。
- 临床决策时需结合患者个体背景,不应仅凭地区差异判断安全性优劣。
局限性
- 仅纳入2019年8月前发表的随机对照试验,可能未涵盖后续新证据。
- Meta回归调整个体背景后安全性地区差异不显著,提示原始安全性差异可能受混杂因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Direct oral anticoagulants (DOACs) have increasingly replaced warfarin for treating patients with non-valvular atrial fibrillation (NVAF). DOACs have been demonstrated to be more useful than warfarin, which was highlighted at its ethnic differences in efficacy and safety; however, the regional differences of DOACs remain unclear. We conducted a systematic review, meta-analysis, and meta-regression to evaluate the efficacy and safety of DOACs in patients from Asian and non-Asian regions with NVAF. We systematically searched randomized control trials published before August 2019. We defined 11 studies comprising 7,118 Asian and 53,282 non-Asian patients, totaling 60,400 patients with NVAF. The risk ratios (RRs) of DOACs were calculated against warfarin. The efficacy of DOACs was significantly higher in Asian regions regarding stroke/systemic embolism events (RR: 0.62 and 95% confidence interval (CI): 0.49-0.78 for the Asian region; RR: 0.83 and 95% CI: 0.75-0.92 for non-Asian regions; P interaction: 0.02), when compared with warfarin. The safety of DOACs was significantly higher in Asian regions regarding major bleeding (RR: 0.62 and 95% CI: 0.51-0.75 for Asian regions; RR: 0.90 and 95% CI: 0.76-1.05 for non-Asian regions; P interaction: 0.004), compared with warfarin. In addition, we conducted meta-regression analysis to discuss the true regional differences of DOACs to warfarin. The meta-regression analysis, which adjusts the effect of individual backgrounds in each study, indicated that the regional differences were observed in the efficacy but not in drug safety. These results suggest that treatment with DOACs may be more effective than the conventional warfarin in the Asian region.
引用
- Ambe K, Akita A, Wei J, et al. Comparison of Efficacy and Safety of Direct Oral Anticoagulants and Warfarin between Patients in Asian and Non-Asian Regions: A Systematic Review and Meta-Regression Analysis. Clin Pharmacol Ther. 2023. PMID: 36861312. doi:10.1002/cpt.2881
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。